Author(s) Lázaro-Martínez JL, García-Morales E, Beneit-Montesinos JV, Martínez-de-Jesús FR, Aragón-Sánchez FJ, et al.

Journal Cirugia espanola. Date of publication 2007 Jul 1;volume 82(1):27-31.

Abstract 1. Cir Esp. 2007 Jul;82(1):27-31. [Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers]. [Article in Spanish] Lázaro-Martínez JL(1), García-Morales E, Beneit-Montesinos JV, Martínez-de-Jesús FR, Aragón-Sánchez FJ. Author information: (1)Unidad de Pie Diabético, Clínica Universitaria de Podología, Universidad Complutense de Madrid, Madrid, Spain. diabetes@enf.ucm.es INTRODUCTION: Diabetic foot is a complication of diabetes mellitus that manifests with the development of ulcers that frequently precede amputation. Several studies have verified that the environment of the diabetic neuropathic foot ulcer contains a high concentration of metalloproteinases. The aim of the present study was to evaluate the efficacy of a protease-modulating dressing in the treatment of neuropathic diabetic foot ulcers. MATERIAL AND METHOD: A randomized controlled trial was conducted in 40 patients with a 6-week or longer history of neuropathic diabetic foot ulcer. The patients were randomized to two groups: group 1 (n = 20) received treatment with the protease-modulating dressing while the control group (group 2; n = 20) received the treatment specified in the standardized protocol for good wound care. The patients were then followed-up for 6 weeks. RESULTS: After 6 weeks, healing was achieved in 12 patients (63% of n = 19) in group 1 under treatment with the protease-modulating dressing versus three patients (15% of n = 19) in the control group (p < 0.03). The mean time to healing was 23.3 +/- 9.9 days in group 1 and 40.6 +/- 1.15 days in group 2 (p < 0.01). CONCLUSIONS: The results confirm the hypothesis that the use of protease-modulating dressings in patients with neuropathic diabetic foot ulcers leads to better tissue regeneration than good wound care. PMID: 17580028 [Indexed for MEDLINE]

Source ID (e.g. PMID): 17580028